The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Bakulin I.G.

I.I. Mechnikov North-Western State Medical University

Zhuravleva M.S.

I.I. Mechnikov North-Western State Medical University

Khapat M.N.

I.I. Mechnikov North-Western State Medical University

Zaitseva A.M.

I.I. Mechnikov North-Western State Medical University

Sologub D.V.

I.I. Mechnikov North-Western State Medical University

Hyperuricemia as therapeutic target in the metabolic dysfunction-associated steatotic liver disease

Authors:

Bakulin I.G., Zhuravleva M.S., Khapat M.N., Zaitseva A.M., Sologub D.V.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2025;28(10): 93‑98

DOI: 10.17116/profmed20252810193

Read: 197 times

Download PDF (RU)
Contact the author
Table of contents

HYPERURICEMIA AS THERAPEUTIC TARGET IN THE METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
HYPERURICEMIA AS THERAPEUTIC TARGET IN THE METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE

To cite this article:

Bakulin IG, Zhuravleva MS, Khapat MN, Zaitseva AM, Sologub DV. Hyperuricemia as therapeutic target in the metabolic dysfunction-associated steatotic liver disease. Russian Journal of Preventive Medicine. 2025;28(10):93‑98. (In Russ.)
https://doi.org/10.17116/profmed20252810193

Подписка 2026 Профилактическая медицина (Russian Journal of Preventive Medicine)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Multiparametric ultrasound effe­ctiveness in dete­cting and moni­toring non-alcoholic fatty liver disease. Russian Journal of Evidence-Based Gastroenterology. 2024;(4):25-33
Effect of uric acid on the progression of Parkinson’s disease: Myth or reality?. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):7-14
Abstract:

Hyperuricemia, defined as an increase in the level of blood uric acid over 360 μmol/L, is currently attracting the attention of researchers due to its high prevalence and potentially adverse effects on the development and progression of major chronic non-communicable diseases. According to epidemiological data, the prevalence of asymptomatic hyperuricemia in the European population reaches 21%, and 4% for gout.

OBJECTIVE

To systematize the published data on the effect of hyperuricemia on the progression of steatosis and fibrosis of the liver in patients with metabolic dysfunction-associated steatotic liver disease.

MATERIALS AND METHODS

The PubMed, Medline, and eLibrary.ru databases were searched for papers published between 2004 and 2024 using the following keywords: «hyperuricemia», «gout», «uric acid», «fatty liver disease», «steatotic liver disease», «steatohepatitis», «fatty liver degeneration», «metabolic syndrome», and «obesity».

RESULTS

According to observational studies and meta-analyses, in patients with hyperuricemia, the odds ratio for the development of hepatic steatosis is 1.74—2.97, and 1.47—2.98 for hepatic fibrosis.

CONCLUSION

The published data supporting the pathogenetic association between hyperuricemia and metabolic dysfunction-associated steatotic liver disease indicate the need to correct uric acid levels using non-drug measures and urate-lowering pharmacotherapy in patients with metabolic dysfunction-associated steatotic liver disease.

Keywords:

hyperuricemia
uric acid (UA)
metabolic dysfunction-associated steatotic liver disease (MASLD)
liver steatosis
liver fibrosis

Authors:

Bakulin I.G.

I.I. Mechnikov North-Western State Medical University

Zhuravleva M.S.

I.I. Mechnikov North-Western State Medical University

Khapat M.N.

I.I. Mechnikov North-Western State Medical University

Zaitseva A.M.

I.I. Mechnikov North-Western State Medical University

Sologub D.V.

I.I. Mechnikov North-Western State Medical University

Received:

15.04.2025

Accepted:

24.05.2025

Close metadata

References:

  1. Drapkina OM, Mazurov VI, Martynov AI, et al. «Focus on hyperuricemia». The resolution of the Expert Council. Kardiovaskuljarnaja terapija i profilaktika. 2023;22(4):77-84. (In Russ.). https://doi.org/10.15829/1728-8800-2023-3564
  2. Drapkina OM, Mazurov VI, Martynov AI, et al. Consensus statement on the management of patients with asymptomatic hyperuricemia in general medical practice. Kardiovaskuljarnaja terapija i profilaktika. 2024;23(1):89-92. (In Russ.). https://doi.org/10.15829/1728-8800-2024-3737
  3. Mironova OI. Hyperuricemia and kidney damage in patients with cardiovascular disease: A review. Terapevticheskii arkhiv. 2022;94(12):1426-1430. (In Russ.). https://doi.org/10.26442/00403660.2022.12.201999
  4. Bove M, Cicero AFG, Veronesi M, et al. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia. Vascular Health and Risk Management. 2017;13:23-28.  https://doi.org/10.2147/VHRM.S115080
  5. Shalnova SA, Deev AD, Artamonov GV, et al. Hyperuricemia and its correlates in the russian population (results of esse-rf epidemiological study). Racional’naja farmakoterapija v kardiologii. 2014;10(2):153-159. (In Russ.). https://doi.org/10.20996/1819-6446-2014-10-2-153-159
  6. Johnson RJ, Titte S, Cade JR, et al. Uric acid, evolution and primitive cultures. Seminars in Nephrology. 2005;25(1):3-8.  https://doi.org/10.1016/j.semnephrol.2004.09.002
  7. Waheed Y, Yang F, Sun D. Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease. Korean Journal of Internal Medicine. 2021;36:1281-1293. https://doi.org/10.3904/kjim.2020.340
  8. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. https://doi.org/10.1097/HEP.0000000000000323
  9. Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023; 78(6):1966-1986. https://doi.org/10.1097/HEP.0000000000000520
  10. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Journal of Hepatology. 2016;64(6):1388-1402. https://doi.org/10.1016/j.jhep.2015.11.004
  11. Ozhirenie. Klinicheskie rekomendacii. 2024. Accessed June 20, 2025. (In Russ.). https://cr.minzdrav.gov.ru/preview-cr/28_3
  12. Duan H, Zhang R, Chen X, et al. Associations of Uric Acid with Liver Steatosis and Fibrosis Applying Vibration Controlled Transient Elastography in the United States: A Nationwide Cross-Section Study. Frontiers in Endocrinology. 2022;13:930224. https://doi.org/10.3389/fendo.2022.930224
  13. Darmawan G, Hamijoyo L, Hasan I. Association between serum uric acid and Non-alcoholic fatty liver disease: A Meta-Analysis. Acta Medica Indonesiana. 2017;49(2):136-147. 
  14. Sun Q, Zhang T, Manji L, et al. Association between serum uric acid and Non-alcoholic fatty liver disease: An Updated Systematic review and Meta-analysis. Clinical Epidemiology. 2023;15:683-693.  https://doi.org/10.2147/CLEP.S403314
  15. Copur S, Atalay Demiray A, Kanbay M. Uric acid in metabolic syndrome: Does uric acid have a definitive role? European Journal of Internal Medicine. 2022;103:4-12.  https://doi.org/10.1016/j.ejim.2022.04.022
  16. Johnson RJ, Bakris GL, Borghi C, et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the national kidney foundation. American Journal of Kidney Diseases. 2018;71:851-865.  https://doi.org/10.1053/j.ajkd.2017.12.009
  17. Zheng J, Li X, Zhang Y, et al. Hyperuricemia as an effect modifier of the association between metabolic phenotypes and nonalcoholic fatty liver disease in Chinese population. Journal of Translational Medicine. 2023;21:39.  https://doi.org/10.1186/s12967-022-03850-5
  18. Zhou M, Yang N, Xing X. Obesity interacts with hyperuricemia on the severity of non-alcoholic fatty liver disease. BMJ Gastroenterology. 2021;21:43.  https://doi.org/10.1186/s12876-021-01615-w
  19. Yen P-C, Chou Y-T, Li C-H, et al. Hyperuricemia Is Associated with Significant Liver Fibrosis in Subjects with Nonalcoholic Fatty Liver Disease, but Not in Subjects without It. Journal of Clinical Medicine. 2022;11:1445. https://doi.org/10.3390/jcm11051445
  20. Francque SM, Marchesini G, Kautz A, et al. Non-alcoholic fatty liver disease: A patient guideline. Journal of Hepatology. 2021;3(5):100322. https://doi.org/10.1016/j.jhepr.2021.100322
  21. Nealkogol'naja zhirovaja bolezn' pecheni u vzroslyh. Klinicheskie rekomendacii. 2024. Accessed June 20, 2025. (In Russ.). https://rsls.ru/files/KRNGBP2024.pdf
  22. Ambulatornaja gepatologija. Rukovodstvo dlja vrachej. Pod red. IG Bakulina. M., 2024. (In Russ.).
  23. Bakulin IG, Abatsieva MP, Skalinskaya MI, et al. Clinical and medico-social significance of NAFLD through the prism of comorbidity. Terapija. 2019;5(6):76-86. (In Russ.). https://doi.org/10.18565/therapy.2019.6.76-86
  24. Demidova TY, Ushanova FO. Non-alcoholic fatty liver disease: aspects of management of a comorbid patient. A review. Terapevticheskii arkhiv. 2023; 95(10):888-895. (In Russ.). https://doi.org/10.26442/00403660.2023.10.202435
  25. Nakatsu Y, Seno Y, Kushiyama A, et al. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model. American Journal of Physiology. Gastrointestinal and Liver Physiology. 2015;309(1):G42-51.  https://doi.org/10.1152/ajpgi.00443.2014
  26. Al-Shargi A, El Kholy AA, Adel A, et al. Allopurinol versus Febuxostat: A New Approach for the Management of Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease. Biomedicines. 2023; 11(11):3074. https://doi.org/10.3390/biomedicines11113074
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.